Cargando…
Minimally invasive local therapies for liver cancer
Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296086/ https://www.ncbi.nlm.nih.gov/pubmed/25610708 http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001 |
_version_ | 1782352929816051712 |
---|---|
author | Li, David Kang, Josephine Golas, Benjamin J. Yeung, Vincent W. Madoff, David C. |
author_facet | Li, David Kang, Josephine Golas, Benjamin J. Yeung, Vincent W. Madoff, David C. |
author_sort | Li, David |
collection | PubMed |
description | Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown to increase overall survival. Surgical resection and/or transplantation, locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments, providing improved survival outcomes for both primary and metastatic tumors. Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors. For patients with low volume disease, these therapies have now been established into consensus practice guidelines. This review highlights technical aspects and outcomes of commonly utilized, minimally invasive local therapies including laparoscopic liver resection (LLR), radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and stereotactic body radiation therapy (SBRT). In addition, the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed. |
format | Online Article Text |
id | pubmed-4296086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Chinese Anti-Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-42960862015-01-21 Minimally invasive local therapies for liver cancer Li, David Kang, Josephine Golas, Benjamin J. Yeung, Vincent W. Madoff, David C. Cancer Biol Med Review Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown to increase overall survival. Surgical resection and/or transplantation, locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments, providing improved survival outcomes for both primary and metastatic tumors. Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors. For patients with low volume disease, these therapies have now been established into consensus practice guidelines. This review highlights technical aspects and outcomes of commonly utilized, minimally invasive local therapies including laparoscopic liver resection (LLR), radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and stereotactic body radiation therapy (SBRT). In addition, the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed. Chinese Anti-Cancer Association 2014-12 /pmc/articles/PMC4296086/ /pubmed/25610708 http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001 Text en 2015 Cancer Biology & Medicine This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Review Li, David Kang, Josephine Golas, Benjamin J. Yeung, Vincent W. Madoff, David C. Minimally invasive local therapies for liver cancer |
title | Minimally invasive local therapies for liver cancer |
title_full | Minimally invasive local therapies for liver cancer |
title_fullStr | Minimally invasive local therapies for liver cancer |
title_full_unstemmed | Minimally invasive local therapies for liver cancer |
title_short | Minimally invasive local therapies for liver cancer |
title_sort | minimally invasive local therapies for liver cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296086/ https://www.ncbi.nlm.nih.gov/pubmed/25610708 http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001 |
work_keys_str_mv | AT lidavid minimallyinvasivelocaltherapiesforlivercancer AT kangjosephine minimallyinvasivelocaltherapiesforlivercancer AT golasbenjaminj minimallyinvasivelocaltherapiesforlivercancer AT yeungvincentw minimallyinvasivelocaltherapiesforlivercancer AT madoffdavidc minimallyinvasivelocaltherapiesforlivercancer |